Sensitivity and specificity of the reporting of malignant mesothelioma
DOI:
https://doi.org/10.4025/ciencuidsaude.v20i0.55219Keywords:
Mesothelioma, Asbestos, Public health, Epidemiology, Information systemsAbstract
Objective: To measure the sensitivity and specificity of the reporting of malignant mesothelioma in the Population-Based Cancer Registry in Curitiba, PA, Brazil. Method: Retrospective, cross-sectional study conducted in the Population-Based Cancer Registry in Curitiba and 11 reporting institutions, from January to December 2017. The final sample was composed of 92 medical records of adult patients, with diagnoses and reporting of cancer, with topographical codes C38 (pleura, heart, and mediastinum) and C48 (peritoneum and retroperitoneum). Stata 14 was used to analyze sensitivity and specificity, and internal consistency. Each medical record (considered the gold standard) provided by the reporting institutions was compared to those in the registry. Results: The registry sensitivity in reporting mesothelioma (ICD-10: C45) and pleural cancer (ICD-10: C38.4) was 100% (8/8) and 50% (1/2), respectively. Specificity was 90.2% (74/82), as eight cases were wrongly classified as pleural cancer. Conclusions: the registry presented high sensitivity in the reporting of malignant mesothelioma, with no underreporting, and overestimated pleural cancer reporting (nine instead of one) due to erroneous and misleading reporting.
Downloads
Download data is not yet available.
References
1. Amin W, Linkov F, Landsittel DP, Silverstein JC, Bashara W, Gaudioso C et al. Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank cohort. F1000Res. 2018 Jun 3; 7:1184.
DOI: https://dx.doi.org/10.12688%2Ff1000research.15512.3
2. Tian L, Zeng R, Wang X, Shen C, Lai Y, Mingming W, et al. Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis. Oncotarget. 2017;8 (28):46425-46435. DOI: https://doi.org/10.18632/oncotarget.17436
3. Baran FDP, Mercês NNA, Sarquis LMM, Rosa LM. The mesothelioma disease in the perspective of the family caregiver. CiencCuidSaude. 2018 Jul-Set; 17(3):e40645. DOI: https://doi.org/10.4025/cienccuidsaude.v17i3.40645
4. Terracini B, Mirabelli D. Asbestos and product defence science. Int J Epidemiol. 2016 Jun; 45(3):614-8. DOI: https://doi.org/10.1093/ije/dyw136.
5. Marinaccio A, Corfiati M, Binazzi A, Di Marzio D, Bonafede M, Verardo M, et al. The epidemiological surveillance of malignant mesothelioma in Italy (1993-2015): methods, findings, and research perspectives. Epidemiol Prev.2020 Jan-Feb;44(1): 23-30. DOI: https://doi.org/10.19191/ep20.1.p023.014
6. Ministério da Saúde (BR). Instituto Nacional do Câncer José de Alencar Gomes da Silva (INCA). Câncer no Brasil: dados dos registros de bases populacional. Rio de Janeiro: INCA; 2010. v.4.
7. Terracini B, Pedra F, Otero U. Asbestos-related cancers in Brazil. Cad SaúdePública. 2015 May;31(5):903-905. DOI: http://dx.doi.org/10.1590/0102-311XPE010515
8. German RR, Lee LM, Horan JM, Milstein RL, Pertowski CA, Waller MN, et al. Updated Guidelines for Evaluating Public Health Surveillance Systems: recommendations from the Guidelines Working Group Centers for Disease Control and Prevention. MMWR Recomm. Rep. 2001 Jul 27 [cited 2020 Oct 21]; 50(RR-13):1-35. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5013a1.htm
9. Universidade Federal da Bahia (UFBA). Mortalidade e morbidade dos agravos à saúde relacionados ao amianto no Brasil, 2000 a 2011 [Internet] 2012 [acesso 2017 Jun 16]; 2(5):1-6. Available from: http://renastonline.ensp.fiocruz.br/sites/default/files/arquivos/recursos/bol7_amiantoF9.pdf
10. Geltner C, Errhalt P, Baumgartner B, Ambrosch G, Machan B, Eckmayr J, et al. Management of malignant pleural mesothelioma – part 1: epidemiology, diagnosis, and staging. Consensus of the Austrian Mesothelioma Interest Group (AMIG). Wien Klin Wochenschr. 2016 Sep 12;128 (17):611–617. DOI: https://dx.doi.org/10.1007%2Fs00508-016-1080-z
11. Trotta A, Santana VS, Alazraqui M. Mortalidad por mesotelioma en Argentina, 1980-2013. SaludColectiva. 2017 Jan-Mar; 13(1):35-44. DOI: https://doi.org/10.18294/sc.2017.1027
12. GBD 2016 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 84 behavioral, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017 Sep 16;390(10100):1345-1422. DOI: https://doi.org/10.1016/S0140-6736(17)32366-8
13. Koller FJ, Sarquis LMM, Mantovani MF, Miranda FMDA, Consonni D, Mensi C. Monitoring of mesothelioma in Southern Brazil: a situation to be investigated. CogitareEnferm.2017 Jan-Mar;22(1):1-6. DOI: http://dx.doi.org/10.5380/ce.v22i1.49192
14. Santana VS, Algranti E, Campos FBSW, Cavalcante FAUD, Salvi LBSC, Santos SA, et al. Recovering missing mesothelioma deaths in death certificates using hospital records. Am J Ind Med. 2018 Jul; 61(7):547-555. DOI: https://doi.org/10.1002/ajim.22846.
15. Algranti E, Ramos-Bonilla JP, Terracini B, Santanna VS, Comba P, Pasetto R, et al. Prevention of Asbestos Exposure in Latin America within a Global Public Health Perspective. Ann Glob Health. 2019 Mar 29; 85(1): 49,1-15. DOI: http://doi.org/10.5334/aogh.2341
16. Algranti E, Saito CA, Carneiro AP, Moreira B, Mendonça EM, Bussacos MA. The next mesothelioma wave: mortality trends and forecast to 2030 in Brazil. Cancer Epidemiol. 2015 Oct;39(5):687-92. DOI: https://doi.org/10.1016/j.canep.2015.08.007
17. Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Pi̱eros M, et al., editors. Cancer Incidence in Five Continents: IARC Scientific Publication No. 164 РVol. X. [Internet]. Lyon, FRA: International Agency for Research on Cancer; 2014. [Cited 2020 Nov 21]. Available from: https://ci5.iarc.fr/cI5I-x/old/vol10/CI5vol10.pdf
18. Le Stang N, Belot A, GilqSoitIlg A, Rolland P, Astoul P, Bara S, et al. Evolution of pleural cancers and malignant pleural mesothelioma incidence in France between 1980 and 2005. Int J Cancer. 2010 Jan 1;126(1):232-238. DOI: https://doi.org/10.1002/ijc.24711
19.Oliveira AS, Vasconcelos MMN, Abath MB, Paes IMBS, Lemos EC. Registros Hospitalares de Câncer em Pernambuco: da Gestão ao Registro. Rev. Bras. de Cancerol. 2017; 63(1):21-28. DOI: https://doi.org/10.32635/2176-9745.RBC.2017v63n1.152
20. Halfeld TLF, Marcondes L, Kalinke LP, Consonni D, Mensi C, Sarquis LMM. Malignant mesothelioma cases in 20 years of a hospital cancer records.Adv.Nurs. Health, 2019 Oct; 1:85-97. Disponívelem: http://dx.doi.org/10.5433/anh.2019v1.id38068
DOI: https://dx.doi.org/10.12688%2Ff1000research.15512.3
2. Tian L, Zeng R, Wang X, Shen C, Lai Y, Mingming W, et al. Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis. Oncotarget. 2017;8 (28):46425-46435. DOI: https://doi.org/10.18632/oncotarget.17436
3. Baran FDP, Mercês NNA, Sarquis LMM, Rosa LM. The mesothelioma disease in the perspective of the family caregiver. CiencCuidSaude. 2018 Jul-Set; 17(3):e40645. DOI: https://doi.org/10.4025/cienccuidsaude.v17i3.40645
4. Terracini B, Mirabelli D. Asbestos and product defence science. Int J Epidemiol. 2016 Jun; 45(3):614-8. DOI: https://doi.org/10.1093/ije/dyw136.
5. Marinaccio A, Corfiati M, Binazzi A, Di Marzio D, Bonafede M, Verardo M, et al. The epidemiological surveillance of malignant mesothelioma in Italy (1993-2015): methods, findings, and research perspectives. Epidemiol Prev.2020 Jan-Feb;44(1): 23-30. DOI: https://doi.org/10.19191/ep20.1.p023.014
6. Ministério da Saúde (BR). Instituto Nacional do Câncer José de Alencar Gomes da Silva (INCA). Câncer no Brasil: dados dos registros de bases populacional. Rio de Janeiro: INCA; 2010. v.4.
7. Terracini B, Pedra F, Otero U. Asbestos-related cancers in Brazil. Cad SaúdePública. 2015 May;31(5):903-905. DOI: http://dx.doi.org/10.1590/0102-311XPE010515
8. German RR, Lee LM, Horan JM, Milstein RL, Pertowski CA, Waller MN, et al. Updated Guidelines for Evaluating Public Health Surveillance Systems: recommendations from the Guidelines Working Group Centers for Disease Control and Prevention. MMWR Recomm. Rep. 2001 Jul 27 [cited 2020 Oct 21]; 50(RR-13):1-35. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5013a1.htm
9. Universidade Federal da Bahia (UFBA). Mortalidade e morbidade dos agravos à saúde relacionados ao amianto no Brasil, 2000 a 2011 [Internet] 2012 [acesso 2017 Jun 16]; 2(5):1-6. Available from: http://renastonline.ensp.fiocruz.br/sites/default/files/arquivos/recursos/bol7_amiantoF9.pdf
10. Geltner C, Errhalt P, Baumgartner B, Ambrosch G, Machan B, Eckmayr J, et al. Management of malignant pleural mesothelioma – part 1: epidemiology, diagnosis, and staging. Consensus of the Austrian Mesothelioma Interest Group (AMIG). Wien Klin Wochenschr. 2016 Sep 12;128 (17):611–617. DOI: https://dx.doi.org/10.1007%2Fs00508-016-1080-z
11. Trotta A, Santana VS, Alazraqui M. Mortalidad por mesotelioma en Argentina, 1980-2013. SaludColectiva. 2017 Jan-Mar; 13(1):35-44. DOI: https://doi.org/10.18294/sc.2017.1027
12. GBD 2016 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 84 behavioral, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017 Sep 16;390(10100):1345-1422. DOI: https://doi.org/10.1016/S0140-6736(17)32366-8
13. Koller FJ, Sarquis LMM, Mantovani MF, Miranda FMDA, Consonni D, Mensi C. Monitoring of mesothelioma in Southern Brazil: a situation to be investigated. CogitareEnferm.2017 Jan-Mar;22(1):1-6. DOI: http://dx.doi.org/10.5380/ce.v22i1.49192
14. Santana VS, Algranti E, Campos FBSW, Cavalcante FAUD, Salvi LBSC, Santos SA, et al. Recovering missing mesothelioma deaths in death certificates using hospital records. Am J Ind Med. 2018 Jul; 61(7):547-555. DOI: https://doi.org/10.1002/ajim.22846.
15. Algranti E, Ramos-Bonilla JP, Terracini B, Santanna VS, Comba P, Pasetto R, et al. Prevention of Asbestos Exposure in Latin America within a Global Public Health Perspective. Ann Glob Health. 2019 Mar 29; 85(1): 49,1-15. DOI: http://doi.org/10.5334/aogh.2341
16. Algranti E, Saito CA, Carneiro AP, Moreira B, Mendonça EM, Bussacos MA. The next mesothelioma wave: mortality trends and forecast to 2030 in Brazil. Cancer Epidemiol. 2015 Oct;39(5):687-92. DOI: https://doi.org/10.1016/j.canep.2015.08.007
17. Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Pi̱eros M, et al., editors. Cancer Incidence in Five Continents: IARC Scientific Publication No. 164 РVol. X. [Internet]. Lyon, FRA: International Agency for Research on Cancer; 2014. [Cited 2020 Nov 21]. Available from: https://ci5.iarc.fr/cI5I-x/old/vol10/CI5vol10.pdf
18. Le Stang N, Belot A, GilqSoitIlg A, Rolland P, Astoul P, Bara S, et al. Evolution of pleural cancers and malignant pleural mesothelioma incidence in France between 1980 and 2005. Int J Cancer. 2010 Jan 1;126(1):232-238. DOI: https://doi.org/10.1002/ijc.24711
19.Oliveira AS, Vasconcelos MMN, Abath MB, Paes IMBS, Lemos EC. Registros Hospitalares de Câncer em Pernambuco: da Gestão ao Registro. Rev. Bras. de Cancerol. 2017; 63(1):21-28. DOI: https://doi.org/10.32635/2176-9745.RBC.2017v63n1.152
20. Halfeld TLF, Marcondes L, Kalinke LP, Consonni D, Mensi C, Sarquis LMM. Malignant mesothelioma cases in 20 years of a hospital cancer records.Adv.Nurs. Health, 2019 Oct; 1:85-97. Disponívelem: http://dx.doi.org/10.5433/anh.2019v1.id38068
Downloads
Published
2021-04-23
Issue
Section
Original articles
How to Cite
Marcondes, L., Lage Ferreira Halfeld, T., Consonni, D. ., Mensi, C., Maria Mansano Sarquis, L., & Puchalski Kalinke, L. (2021). Sensitivity and specificity of the reporting of malignant mesothelioma. Ciência, Cuidado E Saúde, 20. https://doi.org/10.4025/ciencuidsaude.v20i0.55219
